Precedo Pharmaceuticals Co., Ltd

Taoshan Jiang

Jing Liu

Li Wang

Qingsong Liu

Beilei Wang

Wenchao Wang

Aoli Wang

Ziping Qi

Hong Wu

Fengming Zou

Yongfei Chen

Jiaxin Wu

Zheng Zhao

The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer. 

EGFR and ALK dual inhibitor

Growing community of inventors

Anhui, China

Taoshan Jiang